{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:16:50Z","timestamp":1791263810693,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"European Union's Seventh Framework Programme","award":["261954"],"award-info":[{"award-number":["261954"]}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.vaccine.2014.08.057","type":"journal-article","created":{"date-parts":[[2014,9,16]],"date-time":"2014-09-16T14:37:50Z","timestamp":1410878270000},"page":"5967-5974","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"title":["Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I\/IIa clinical trial"],"prefix":"10.1016","volume":"32","author":[{"given":"Theresa","family":"Neimert-Andersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonas","family":"Binnmyr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattias","family":"Enoksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joakim","family":"Langeb\u00e4ck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Zettergren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Charlotte","family":"H\u00e4llgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-577X","authenticated-orcid":false,"given":"Henry","family":"Franz\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Lind Enoksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Lafolie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alf","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Al-Tawil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Singer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans","family":"Gr\u00f6nlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1618-4011","authenticated-orcid":false,"given":"Guro","family":"Gafvelin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2014.08.057_bib0005","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/cmdc.201200487","article-title":"Modern subunit vaccines: development, components, and research opportunities","volume":"8","author":"Moyle","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0010","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1016\/j.vaccine.2011.04.046","article-title":"The safety evaluation of adjuvants during vaccine development: the AS04 experience","volume":"29","author":"Garcon","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1586\/erv.11.21","article-title":"Trends in vaccine adjuvants","volume":"10","author":"Schijns","year":"2011","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0020","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.coi.2010.04.004","article-title":"New adjuvants for human vaccines","volume":"22","author":"Mbow","year":"2010","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0025","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1038\/nri3085","article-title":"Vaccines for the twenty-first century society","volume":"11","author":"Rappuoli","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0030","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/nm.3409","article-title":"Key roles of adjuvants in modern vaccines","volume":"19","author":"Reed","year":"2013","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0035","doi-asserted-by":"crossref","first-page":"8965","DOI":"10.1016\/j.vaccine.2011.09.041","article-title":"Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine","volume":"29","author":"Neimert-Andersson","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0040","series-title":"Molecular vaccines","article-title":"Chitosan-based adjuvants","author":"Gafvelin","year":"2013"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0045","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1128\/IAI.71.2.726-732.2003","article-title":"Protective levels of diphtheria-neutralizing antibody induced in healthy volunteers by unilateral priming-boosting intranasal immunization associated with restricted ipsilateral mucosal secretory immunoglobulin a","volume":"71","author":"Mills","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0050","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1016\/j.vaccine.2003.09.012","article-title":"Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan","volume":"22","author":"McNeela","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0055","doi-asserted-by":"crossref","first-page":"8256","DOI":"10.1128\/IAI.73.12.8256-8265.2005","volume":"73","author":"Huo","year":"2005","journal-title":"Infect Immun"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0060","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1016\/j.vaccine.2005.04.021","article-title":"Effective nasal influenza vaccine delivery using chitosan","volume":"23","author":"Read","year":"2005","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0065","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1086\/657087","article-title":"Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues","volume":"202","author":"El-Kamary","year":"2010","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0070","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1056\/NEJMoa1101245","article-title":"Norovirus vaccine against experimental human Norwalk Virus illness","volume":"365","author":"Atmar","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0075","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.vaccine.2006.11.034","article-title":"Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination","volume":"25","author":"Zaharoff","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0080","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1086\/315870","article-title":"Prevention of Haemophilus influenzae type b colonization by vaccination: correlation with serum anti-capsular IgG concentration","volume":"182","author":"Fernandez","year":"2000","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0085","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1600-0463.2010.02674.x","article-title":"Do we need a booster of Hib vaccine after primary vaccination? A study on anti-Hib seroprevalence in Sweden 5 and 15 years after the introduction of universal Hib vaccination related to notifications of invasive disease","volume":"118","author":"Hallander","year":"2010","journal-title":"APMIS"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0090","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1086\/599347","article-title":"Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis","volume":"49","author":"de Voer","year":"2009","journal-title":"Clin Infect Dis: An Off Publ Infect Dis Soc Am"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0095","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1086\/423327","article-title":"Successful induction of protective antibody responses against Haemophilus influenzae type b and diphtheria after transcutaneous immunization with the glycoconjugate polyribosyl ribitol phosphate-cross-reacting material 197 vaccine","volume":"190","author":"Mawas","year":"2004","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0100","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/infdis\/164.5.982","article-title":"Reduction of oropharyngeal carriage of Haemophilus influenzae type b (Hib) in children immunized with an Hib conjugate vaccine","volume":"164","author":"Takala","year":"1991","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0105","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1442-200X.2003.01706.x","article-title":"Effect of aluminum adjuvants on safety and immunogenicity of Haemophilus influenzae type b-CRM197 conjugate vaccine","volume":"45","author":"Kanra","year":"2003","journal-title":"Pediatr Int: Off J Jpn Pediatr Soc"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0110","doi-asserted-by":"crossref","first-page":"6333","DOI":"10.4049\/jimmunol.176.10.6333","article-title":"T cell responses are better correlates of vaccine protection in the elderly","volume":"176","author":"McElhaney","year":"2006","journal-title":"J Immunol"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0115","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1016\/j.vaccine.2011.02.022","article-title":"A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2 \u2013 a GLURP-MSP3 fusion protein malaria vaccine candidate","volume":"29","author":"Lousada-Dietrich","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0120","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/nprot.2009.7","article-title":"The role of IFN-gamma Elispot assay in HIV vaccine research","volume":"4","author":"Streeck","year":"2009","journal-title":"Nat Protoc"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0125","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1586\/erv.12.125","article-title":"Pushing the frontiers of T-cell vaccines: accurate measurement of human T-cell responses","volume":"11","author":"Saade","year":"2012","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0130","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1084\/jem.152.2.361","article-title":"Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates","volume":"152","author":"Schneerson","year":"1980","journal-title":"J Exp Med"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0135","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1021\/cb400423g","article-title":"Recent mechanistic insights on glycoconjugate vaccines and future perspectives","volume":"8","author":"Berti","year":"2013","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0140","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/nm.2535","article-title":"A mechanism for glycoconjugate vaccine activation of the adaptive immune system and its implications for vaccine design","volume":"17","author":"Avci","year":"2011","journal-title":"Nat Med"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0145","doi-asserted-by":"crossref","first-page":"20976","DOI":"10.1073\/pnas.1115973108","article-title":"Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing","volume":"108","author":"Sun","year":"2011","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.vaccine.2014.08.057_bib0150","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1517\/17425247.2013.739156","article-title":"Injectable hydrogel therapies and their delivery strategies for treating myocardial infarction","volume":"10","author":"Johnson","year":"2013","journal-title":"Expert Opin Drug Deliv"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011955?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X14011955?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T06:47:32Z","timestamp":1589266052000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X14011955"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":30,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["S0264410X14011955"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.057","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of safety and efficacy as an adjuvant for the chitosan-based vaccine delivery vehicle ViscoGel in a single-blind randomised Phase I\/IIa clinical trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2014.08.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}